ticker nerd logo
Illumina Inc

Illumina Inc Stock Forecast & Price Prediction

Live Illumina Inc Stock (ILMN) Price
$140.05

15

Ratings

  • Buy 7
  • Hold 6
  • Sell 2
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$140.05

P/E Ratio

P/E Ratio not available for ILMN

Volume Traded Today

$1.3M

Dividend

Dividends not available for ILMN

52 Week High/low

238.55/89.00

Illumina Inc Market Cap

$22.79B

🛑 Alert: These ten stocks could have higher potential than $ILMN 🛑

Before you buy ILMN you’ll want to see this list of ten stocks that have huge potential. Want to see if ILMN made the cut? Enter your email below

ILMN Summary

From what 15 stock analysts predict, the share price for Illumina Inc (ILMN) might increase by 10.39% in the next year. This is based on a 12-month average estimation for ILMN. Price targets go from $85.00 to $258.00. The majority of stock analysts believe ILMN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

ILMN Analyst Ratings

ILMN is a stock in Health Care which has been forecasted to be worth $154.60 as an average. On the higher end, the forecast price is $258.00 USD by conor mcnamara from RBC Capital and on the lower end ILMN is forecasted to be $85.00 by luke sergott from Barclays.

ILMN stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

patrick b donnelly
Citi

Hold

$145.0

reiterated

Feb 9, 2024
daniel brennan
TD Cowen

Hold

$150.0

maintained

Feb 8, 2024
catherine ramsey schulte
Robert W. Baird

Hold

$144.0

maintained

Jan 29, 2024
kyle mikson cfa
Canaccord Genuity

Hold

$130.0

maintained

Jan 16, 2024
shubhangi gupta
HSBC

Hold

$150.0

downgraded

Jan 15, 2024
eve burstein
Bernstein

Hold

$127.0

upgraded

Dec 15, 2023
john sourbeer
UBS

Hold

$111.0

maintained

Nov 10, 2023
rachel vatnsdal
J.P. Morgan

Hold

$110.0

maintained

Nov 10, 2023
dan leonard
Credit Suisse

Hold

$200.0

rated

Aug 9, 2023
tejas savant
Morgan Stanley

Hold

$225.0

maintained

Apr 26, 2023
julia qin
J.P. Morgan

Hold

$235.0

maintained

Apr 26, 2023
tycho peterson
J.P. Morgan

Hold

$235.0

maintained

Apr 26, 2023
jasper hellweg
Argus Research

Hold

None

downgraded

Jan 25, 2023
derik de bruin
Bank of America Securities

Hold

None

maintained

Sep 2, 2022
lorenzo biasio
Credit Suisse

Hold

$270.0

maintained

Aug 17, 2022
james mainwaring
Atlantic Equities

Hold

$390.0

downgraded

Mar 31, 2021
mark massaro
BTIG

Hold

$310.0

maintained

Oct 24, 2019
amanda murphy
BTIG

Hold

None

downgraded

Jan 5, 2018
paul knight
KeyBanc

Hold

None

upgraded

Oct 23, 2017
dane leone
Raymond James

Hold

None

rated

Mar 16, 2017

ILMN Company Information

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN
Illumina Inc (ILMN)

When did it IPO

2000

Staff Count

10,590

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Mr. Jacob Thaysen Ph.D.

Market Cap

$22.79B

Illumina Inc(ILMN) Financial Data

In 2023, ILMN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ILMN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $4.50B
  • Operating Margin TTM -0.03%
  • Gross profit TTM $2.74B
  • Return on assets TTM -0.01%
  • Return on equity TTM -0.19%
  • Profit margin -0.25777%
  • Book value 36.13%
  • Market capitalisation $22.79B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year -7.34
  • EPS next year N/A
... ...

Similar Stocks to Illumina Inc ILMN

🛑 Alert: These ten stocks could have higher potential than $ILMN 🛑

Before you buy ILMN you’ll want to see this list of ten stocks that have huge potential. Want to see if ILMN made the cut? Enter your email below

...

ILMN Frequently asked questions

The highest forecasted price for ILMN is $258.00 from conor mcnamara at RBC Capital.

The lowest forecasted price for ILMN is $85.00 from luke sergott from Barclays

The ILMN analyst ratings consensus are 7 buy ratings, 6 hold ratings, and 2 sell ratings.